Harmony Biosciences (HRMY) Tops Q2 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Harmony Biosciences (HRMY) Tops Q2 EPS by 9c

Harmony Biosciences Reports Second Quarter 2022 Financial Results and Business Updates

August 2, 2022 7:30 AM EDT

WAKIX® (pitolisant) Net Revenue of $107.0 Million for Second Quarter 2022 Increase of 45% vs. the Same Period in 2021

Average Number of Patients on WAKIX Increased to ~4,300

Signs New Agreement with Bioprojet Focused on Developing Innovative Therapeutics Based on Pitolisant, Expanding Harmonys Opportunity in Narcolepsy

Phase 3 Idiopathic Hypersomnia (IH) INTUNE Study on Track with Site Activations and Patient Enrollment

Conference Call and Webcast to be Held Today at 8:30 a.m. ET

PLYMOUTH MEETING, Pa., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Harmony... More